You just read:

Janssen Receives Positive CHMP Opinion Recommending EDURANT®▼ (rilpivirine) for the Treatment of Adolescents Aged 12 to <18 Years with HIV-1 infection

News provided by

Janssen-Cilag International NV

26 Oct, 2015, 08:00 GMT